Arcturus Therapeutics Holdings Inc (ARCT)

The growth-focused money manager only bought three stocks on Wednesday. Let's check out that shopping list.

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at the gap up and gap down stocks in today's session.

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

The company is working on a treatment for cystic fibrosis using messenger RNA, or mRNA, technology.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.